Wagener Nele, Lehmann Wolfgang, Böker Kai O, Röhner Eric, Di Fazio Pietro
Department of Trauma Surgery, Orthopedics and Plastic Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37099 Göttingen, Germany.
Center for Musculoskeletal Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
J Clin Med. 2022 Oct 21;11(20):6218. doi: 10.3390/jcm11206218.
Attention deficit hyperactivity disorder (ADHD) affects 6.4 million children in the United States of America. Children and adolescents, the main consumers of ADHD medication, are in the bone growth phase, which extends over a period of up to two decades. Thus, impaired proliferation and maturation of chondrocytes and osteoblasts can result in impaired bone formation. The aim of this study is to investigate, for the first time, the effects of the ADHD-medication modafinil, atomoxetine and guanfacine on bone growth and repair in vitro. Using two-dimensional and three-dimensional cell models, we investigated the chondrogenic/osteogenic differentiation, proliferation and viability of human mesenchymal progenitor cells. Real-time cell proliferation was measured by xCELLigence. Live/dead staining and size measurement of hMSC- and MG63 monolayer and spheroids were performed after administration of therapeutic plasma concentrations of modafinil, atomoxetine and guanfacine. Chondrogenic differentiation was quantified by RTqPCR. The chondrogenic and osteogenic differentiation was evaluated by histological cryo-sections. Modafinil, atomoxetine and guanfacine reduced chondrogenic and osteogenic differentiation terms of transcript expression and at the histological level. Cell viability of the MG63- and hMSC monolayer was not impeded by ADHD-medication. Our in vitro results indicate that modafinil, atomoxetine and guanfacine may impair chondrogenic and osteogenic differentiation in a 3D model reflecting the in vivo physiologic condition.
注意力缺陷多动障碍(ADHD)影响着美国640万儿童。儿童和青少年是ADHD药物的主要使用者,他们正处于骨骼生长阶段,这一阶段可持续长达二十年。因此,软骨细胞和成骨细胞的增殖和成熟受损会导致骨形成受损。本研究的目的是首次调查ADHD药物莫达非尼、托莫西汀和胍法辛对体外骨骼生长和修复的影响。我们使用二维和三维细胞模型,研究了人间充质祖细胞的软骨生成/成骨分化、增殖和活力。通过xCELLigence测量实时细胞增殖。在给予莫达非尼、托莫西汀和胍法辛的治疗血浆浓度后,对hMSC和MG63单层细胞及球体进行活/死染色和大小测量。通过RTqPCR对软骨生成分化进行定量。通过组织学冷冻切片评估软骨生成和成骨分化。莫达非尼、托莫西汀和胍法辛在转录表达和组织学水平上降低了软骨生成和成骨分化。ADHD药物并未阻碍MG63和hMSC单层细胞的细胞活力。我们的体外研究结果表明,在反映体内生理状况的三维模型中,莫达非尼、托莫西汀和胍法辛可能会损害软骨生成和成骨分化。